Library.
3 verifications about SURMOUNT-1 SURMOUNT-1 ×
-
False 1/10
“At week 72 of the Phase 3 SURMOUNT-1 trial, the mean percentage change in body weight was -20.9% with once-weekly 5 mg tirzepatide.”
The claim assigns the 15 mg dose’s weight-loss result to the 5 mg dose. At week 72 of the Phase 3 SURMOUNT-1 trial, mean body-weight change was −15.0% with once-weekly 5 mg tirzepatide; −20.9% was the result for 15 mg. The peer-reviewed trial report and FDA records, including the January 2026 label, consistently document this distinction.
-
True 10/10
“The Phase 3 SURMOUNT-1 trial enrolled 2,539 adults without diabetes who had a body-mass index of at least 30, or at least 27 with at least one weight-related complication.”
The enrollment total and eligibility criteria are accurately stated. The primary trial publication, FDA review and official registry confirm that Phase 3 SURMOUNT-1 enrolled 2,539 adults without diabetes, with a BMI of at least 30, or at least 27 with at least one weight-related complication. Additional eligibility requirements do not change the accuracy of this summary.
-
True 10/10
“In the Phase 3 SURMOUNT-1 trial, participants received once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks.”
The claim accurately describes the treatment arms and primary duration of SURMOUNT-1. The primary NEJM report, study protocol and trial registry confirm that this phase 3 trial assigned participants to once-weekly subcutaneous tirzepatide at target doses of 5 mg, 10 mg or 15 mg, or placebo, over 72 weeks.